ClinicalTrials.gg
RecruitingNCT06334588ECLATUpdated Dec 23, 2025

Understanding the Mechanisms of Autism : an MRI and Social Cognition Study

An interventional study of MRI and Eye-tracking in Autism Spectrum Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 3 Months to 28 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
3 Months to 28 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris — 10 open to participants now, 11 under way, none of them phase 3. Autism Spectrum Disorder · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 13
160 · median 27
Started
2024
with 2 others
No phase
9 of 17
5 open now
Primary completion
2029-04
later than 9 of 10 live
Registered
12th of 17
by date

Among the 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 12th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

10 of the 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 3 Months to 28 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The main goal of this study is to investigate anatomo-functional brain abnormalities associated with autism spectrum disorders using a multimodal brain imaging approach, as well as its links to social cognition difficulties measured using eye-tracking

Read the detailed description

Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose first manifestations appear early in childhood. Even if ASDs present a wide heterogeneity in clinical manifestations, abnormalities in social behavior, characterized in particular by a lack of preference for social information, remain the core of difficulties characteristic of autism.

Brain imaging investigations have revealed anatomo-functional abnormalities in autism, particularly in social brain regions. In parallel, eye-tracking studies have provided objective measures of social perception abnormalities in autism. These results illustrate the relevance of these research strategies in the context of ASD. Acquiring objective data on social behavior and linking them with brain imaging data opens up new avenues for research into the evolution of social skills during child development, and the brain changes underlying this process.

In this context, the main hypothesis of this study is that the investigation of the neural bases of autism spectrum disorders, using an approach combining multimodal brain imaging and the investigation of social behavior using eye-tracking, would make it possible not only to better describe abnormalities, but also to identify individual patterns at brain and behavioral level. This could help to better characterize ASDs with and without genetic abnormalities, an area which to date has received very little investigation. In addition, the objective measurements obtained with this approach would also enable the proposal of biomarkers, which would contribute not only to better monitoring of the disorder's evolution, but also to the evaluation of the effectiveness of new therapeutic interventions

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism spectrum disorders
  • Multimodal brain imaging
  • Eye-tracking
  • Social perception
  • Genetics
  • Developmental trajectory
04

Who can participate

Ages eligible
3 Months to 28 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For subjects diagnosed with ASD or suspected of ASD :

  • 3 months ≤ age \< 25 years ;
  • an MRI required as part of the clinical procedures
  • written consent obtained from parents or legal guardians.
  • Affiliated to social security

For Healthy control subjects over 3 years of age:

  • between 3 and 28 years of age
  • no known neurological or psychiatric pathology
  • written consent obtained from parents or legal guardian.
  • Affiliated to social security

For Healthy control subjects under 5 years of age:

  • age between 3 months and 5 years
  • who have had an MRI scan in the pediatric radiology department at Necker Hospital, which was found to be normal.
  • with no known neurological or psychiatric pathology
  • no opposition from legal representative

Exclusion criteria

Exclusion Criteria:

  • to MRI (pacemaker, intracorporeal metallic body, claustrophobia).
  • Impossibility for healthy volunteers to remain still during MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Suspected or confirmed Autism Spectrum Disorders (ASD)

    Patient with ASD or suspected ASD for whom an MRI is requested by the clinician as part of care

    Diagnostic Test: MRI · Device: Eye-tracking · Other: Clinical Scales · Genetic: Research of genetic anomalies

  • Experimental
    Healthy volunteers over 3 years of age

    Healthy Control Children will be recruited specifically for the research

    Diagnostic Test: MRI · Device: Eye-tracking · Other: Clinical Scales

  • No intervention
    Healthy volunteers under 5 years of age

    Children who have already undergone an MRI for various medical reasons and whose MRI was normal.

Interventions

  • Diagnostic testMRI

    Anatomical and functional images will be acquired and review by an experienced neuro-radiologist

  • DeviceEye-tracking

    Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera

  • OtherClinical Scales

    CGI, E-CAR and ABC will be used for behavior and clinical evaluation

  • GeneticResearch of genetic anomalies

    For the diagnosis of autism, patients benefit from a a genetic assessment. This is carried out as part of their care

06

What researchers measure

Primary outcomes

  1. Rest cerebral blood flow (CBF)

    Whole brain rest CBF measured with Arterial spin labelling MRI

    Time frame: at inclusion

Secondary outcomes

  1. Measurements of white matter microstructure - fractional anisotropy

    Measurements of white matter microstructure integrity by diffusion tensor imaging MRI, measured by fractional anisotropy (indicates the orientation of diffusion)

    Time frame: at inclusion

  2. Measurements of white matter microstructure - mean diffusivity

    Measurements of white matter microstructure integrity by diffusion tensor imaging MRI, measured by mean diffusivity (the mean amount of diffusion in each of the principal directions calculated in the tensor

    Time frame: at inclusion

  3. Measurements of white matter microstructure - radial diffusivity

    Measurements of white matter microstructure integrity by diffusion tensor imaging MRI, measured by radial diffusivity (the apparent water diffusion coefficient in the direction perpendicular to the axonal fibers)

    Time frame: at inclusion

  4. Measurements of white matter microstructure - axial diffusivity

    Measurements of white matter microstructure integrity by diffusion tensor imaging MRI, measured by axial diffusivity (the magnitude of diffusion parallel to fiber tracts)

    Time frame: at inclusion

  5. Measurements of resting state functional connectivity

    MRI-resting state measurements of correlation coefficients between different regions within different brain networks, in particular the social brain network.

    Time frame: at inclusion

  6. Correlation between social perception and multimodal brain imaging

    Correlation measurements between social perception parameters measured by eye-tracking (number of fixations in social and non-social regions) and various multimodal brain imaging parameters obtained with MRI.

    Time frame: at inclusion

  7. Correlation between clinical severity and multimodal brain imaging

    Measures of correlation between autism severity scores measured by the ADI-R and various multimodal brain imaging parameters obtained in MRI

    Time frame: at inclusion

  8. Imaging abnormalities associated with known genetic mutations

    Multimodal brain imaging in patients with a known genetic abnormality compared with the same measures obtained in patients without known genetic abnormalities or in healthy controls.

    Time frame: at inclusion

  9. Social perception abnormalities associated with known genetic mutations

    Social perception measures (number of fixations in social and non-social regions) in patients with a known genetic abnormality compared with the same measures obtained in patients without known genetic abnormalities or in healthy controls.

    Time frame: at inclusion

  10. Anatomic changes over time - study of developmental trajectory

    Measures of change over time (between inclusion and 2 years) in brain anatomy and function in a subgroup of ASD patients and healthy volunteers.

    Time frame: 2 years

  11. Social perception changes over time - study of developmental trajectory

    Measures of change over time (between inclusion and 2 years) in social perception parameters in a subgroup of ASD patients and healthy volunteers.

    Time frame: 2 years

  12. Brain imaging in young children associated with ASD

    Multimodal brain imaging measures in young patients (\<5 years) with a ASD compared with the same measures obtained in young children (\<5 years) without ASD (control children)

    Time frame: at inclusion

  13. Early data on social perception

    Social perception measures (number of fixations in social and non-social regions) in very young patients with ASD (3 months to 5 years) compared with a subgroup of control children aged under 5 years

    Time frame: at inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2029, 60 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 60 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Mar 28, 2024
StartActual
Apr 17, 2024
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2031
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06334588
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Apr 17, 2024
Primary completion
Apr 2029 (estimated)
Completion
Apr 2031 (estimated)
Last update
Dec 23, 2025

Study contacts

Nathalie BODDAERT, MD, PhD
Contact
nathalie.boddaert@aphp.fr
+33 1.71.39.65.30
Victor BRUYERE, Master
Contact
victor.bruyere@aphp.fr
+ 33 1 34 29 23 24
Monica ZILBOVICIUS
study director · INSERM INSERM ERL "Trajectoires Développementales en Psychiatrie"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion